U.S., Aug. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07116031) titled 'A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)' on July 25.
Brief Summary: This is an open-label, single group, Phase 1/2, 1-arm study for treatment of children aged 1 to <18 years with active moderate-to-severe cGVHD that is refractory to or recurred after at least 2 prior lines of systemic therapy for cGVHD.
The purpose of Phase 1 is to determine the PK profiles and to establish the Recommended Pediatric Equivalent Dose (RPED) of belumosudil in participants aged 1 to <12 years with active moderate to severe cGVHD. Upon completion and evaluation of Phase 1, Phase 2 will commence with the pur...